Next generation sequencing, deep sequencing, or massively parallel sequencing are synonymous terms that are enough to describe the DNA sequencing technology. This technology has revolutionized the genomic study or research. With the help of the next generation sequencing, the overall human genome can be efficiently sequenced in just single day. On the other hand, the previously used Sanger sequencing technology that was more prominently used to decode human genome needed over the period of ten years in order to deliver the ultimate draft. Though next generation sequencing has been mostly used in genome research, it has mostly outdated the traditional Sanger sequencing method. It has not still translated in the routine practice off clinics.
Next Generation Sequencing (NGS) market is estimated to be over US$ 4.0 Bn in 2017. It is anticipated to grow at a CAGR of 18.8% from 2019 to 2030.
The continual growth in clinical application of NGS as well as sequencing of whole or targeted genomes has presented a bright prospect for the growth of global Next Generation Sequencing (NGS) market. Reduction of costs associated with sequencing has further led to wide scale application of such techniques.
Major Key Players of the Next generation sequencing (NGS) Market are:
Agilent Technologies, 10x Genomics, Beckman Coulter (A Subsidiary of Danaher), Becton, Dickinson and Company, Eurofins Scientific, Pacific Biosciences of California, Inc., BGI, Illumina, Inc., F. Hoffmann-La Roche AG, among others.
No comments:
Post a Comment